3 results about "Cornea dystrophy" patented technology

The present invention provides an antisense oligonucleotide pharmaceutical composition for preventing or treating Avellino corneal dystrophy, which induces the suppression of R124H mutant TGFBI protein expression, its use, or a method for treating the same. In particular, the present invention selectively acts on R124H TGFBI mRNA, which is a precursor to the production of R124H mutant TGFBI protein, the causative protein of Avellino corneal dystrophy, thereby minimizing the effect on normal WT TGFBI expression and inducing the inhibition of R124H TGFBI expression, thereby enabling highly effective prevention or treatment of Avellino corneal dystrophy.

The present invention relates to compositions, systems, and methods for treating a subject with an eye condition (e.g., topically) using a composition comprising an ACE-2 receptor antagonist (also known as Angiotensin II Receptor Blocker or “ARB”) (e.g., losartan, telmisartan, valsartan, olmesartan, candesartan, irbesartan, eprosartan, azilsartan, or losartan metabolite EXP3174). In certain embodiments, the eye condition is selected from: i) a corneal scarring fibrosis, ii) a transforming growth factor beta-induced (TGFBI) corneal dystrophy, iii) a conjunctival fibrotic disease, iv) an intraocular fibrotic disease, and v) a conjunctival bleb scarring and / or shunt encapsulation (e.g., following glaucoma surgery).

Provided are methods of treating or preventing corneal endothelial disease. The present disclosure relates to corneal endothelial cell compositions comprising cultured human corneal endothelial cells and a Rho-associated, coiled-coil containing protein kinase inhibitor, and uses of the compositions for the treatment of corneal endothelial diseases, including bullous keratopathy, corneal edema, corneal leukoma, corneal endothelial inflammation, and corneal dystrophy.